The University of British Columbia

The Liposome Company, Inc.

Inex Pharmaceuticals Corporation

Tekmira Pharmaceuticals Corporation

Other

Arbutus Biopharma Corporation

The Lipsome Company, Inc.

Ludwig-maximilians-universitat München

Transave Limited

Mayer, Lawrence D.

Bally, Marcel B.

Madden, Thomas D.

Cullis, Pieter R.

Hope, Michael J.

Fountain, Michael W.

Pieter Rutter Cullis

Muthiah Manoharan

Kallanthottathil G Rajeev

Martin A Maier

Andrew S Janoff

Muthusamy Jayaraman

Akin Akinc

Marcel B Bally

Michael J Hope

Thomas D Madden

Igor V Jigaltsev

Lawrence D Mayer

Marco A Ciufolini

Peter Scherrer

Kim F Wong

Norbert Maurer

Sean C Semple

Richard S Ginsberg

Andre Wild

Nathan Maurice Belliveau

Steven Michial Ansell

Jeffery J Wheeler

Timothy Leaver

Sandra K Klimuk

Troy Harasym

Michael W Fountain

Robert James Taylor

Yuan-Peng Zhang

Helen C Loughrey

George N Mitilenes

Dan Debeyer

Hugh P Schieren

Regina L Jablonski

Dorothy L Reimer

Lorne Ralph Palmer

Jianxin Chen

Carl Lars Genghis Hansen

John J Kearns

Lewis S L Choi

Jayesh Kulkarni

Lewis S Choi

Jens Huft

David E Walker

Alan L Weiner

Lawrence T Boni

Robert P Lenk

Elisabeth Maurer

Joel B Portnoff

Lois E Bolcsak

Ian Clark-Lewis

Euan Ramsay

Robert J Klimchak

Colin Walsh

Dominik Witzigmann

David B Fenske

Anthony G Durning

Ajoy C Chakrabarti

Nancy L Boman

Barbara Low Shoud Mui

Austin Hill

Terri Petkau

Blair Leavitt

Myrna Monck

Austin Bailey

Stuart Malcolm

Ismail Hafez

Alex Leung

Pamela Wagner

James R Taylor

John W Holland

Jo Ann Jedrusiak

Jeffery Jerome Wheeler

Colin P Tilcock

Paul G Tardi

Ljiljana Kojic

Tao Chen

Yuen Yi Tam

Joshua Zaifman

Barbara L S Mui

Austin L Bailey

Jeffrey A Veiro

Maurer Norbert

Johanna M Leenhouts

Erik Swartz

Robert P Link

Igor V Zhigaltsev

Jerome Gaucheron

R James Taylor

Angela M I Lam

Deirdre McIntosh

Nancy Dos Santos

Olga Ludkovski

Edward George Saravolac

Norbert Mauer

Olivia Monika Merkel

Barbara Ls Mui

Colin Ps Tilcock

Huge P Schieren

Fountain Michael W

Joel Portnoff

Limit size lipid nanoparticles, methods for using the lipid nanoparticles, and methods and systems for making limit size lipid nanoparticles.

Limit size lipid nanoparticles and related methods

Lipid-based vesicles, typically herein called transfection competent vesicles (TCVs), configured to safely and efficiently deliver DNA, RNA, other nucleic acid and protein cargoes into target cells. The safety and efficiency are each, and both, achieved in part by eliminating organic solvents such as ethanol and detergents such as sodium dodecyl sulfate from the TCV loading processes (i.e., inserting a cargo into the TCV), TCV storage processes, and/or TCV delivery processes. The cargoes can also comprise nucleic acids complexed with a protein, such as a ribonucleoprotein (RNP). The systems, compositions, devices and methods, etc., herein, in some embodiments, can provide empty TCVs that can if desired be loaded at the bench without use of specialized equipment.

Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto

Microfluidic mixing devices and systems

This invention provides lipid-linked prodrugs having structures as set out herein. Uses of such lipid-linked prodrug compounds for treatment of various indications, and methods for making and using lipid-linked prodrugs are also provided.

Lipid-linked prodrugs

The present invention provides superior compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target proteins at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

Amino lipids and methods for the delivery of nucleic acids

Transfection reagent composition, lipid nanoparticles prepared from the transfection reagent composition, kits that include the transfection reagent composition, and methods for making and using lipid nanoparticles prepared from the transfection reagent composition. Lipids when dispersed in aqueous media readily form liposomes, such as unilamellar vesicles and multilamellar vesicles. Liposomes have been used successfully to encapsulate and deliver a wide range of chemicals including nucleic acids, proteins and small molecule drugs, to cells.

Lipid nanoparticles for transfection and related methods

Lipid particles containing a nucleic acid, devices and methods for making the lipid particles, and methods for using the lipid particles.

Nucleic acid-containing lipid particles and related methods

Drag derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drag derivatized with a weak-base moiety that facilitates active loading of the drag through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drag to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drag derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drags.

Modified drugs for use in liposomal nanoparticles

Drug derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drug derivatized with a weak-base moiety that facilitates active loading of the drug through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drug to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drug derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drugs.

Growing community of inventors

Vancouver, Canada

Pieter Rutter Cullis